K. Slimane

436 total citations
17 papers, 352 citations indexed

About

K. Slimane is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, K. Slimane has authored 17 papers receiving a total of 352 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 9 papers in Molecular Biology and 8 papers in Oncology. Recurrent topics in K. Slimane's work include Renal cell carcinoma treatment (7 papers), Renal and related cancers (7 papers) and Cancer Genomics and Diagnostics (4 papers). K. Slimane is often cited by papers focused on Renal cell carcinoma treatment (7 papers), Renal and related cancers (7 papers) and Cancer Genomics and Diagnostics (4 papers). K. Slimane collaborates with scholars based in France, Switzerland and Algeria. K. Slimane's co-authors include Christophe Massard, C Juhan, Yves Alimi, G. Riepe, Nabil Chakfé, Julien Grenier, Suzette Delaloge, Ariane Dunant, M. Spielmann and Fabrice André and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

K. Slimane

17 papers receiving 332 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K. Slimane France 7 321 123 70 50 45 17 352
Nicola Fenwick United Kingdom 7 154 0.5× 82 0.7× 62 0.9× 50 1.0× 14 0.3× 10 241
Drew Baldwin United States 4 151 0.5× 96 0.8× 22 0.3× 56 1.1× 53 1.2× 6 235
Antonella Fontana Italy 8 148 0.5× 71 0.6× 66 0.9× 54 1.1× 16 0.4× 26 293
Shireen Parsai United States 10 174 0.5× 121 1.0× 14 0.2× 41 0.8× 59 1.3× 30 268
Hirotoshi Kubokura Japan 11 177 0.6× 84 0.7× 17 0.2× 79 1.6× 10 0.2× 32 306
Ivica Ratoša Slovenia 8 84 0.3× 93 0.8× 23 0.3× 24 0.5× 27 0.6× 29 208
Anna Skakodub United States 8 162 0.5× 106 0.9× 13 0.2× 16 0.3× 112 2.5× 16 265
Renchun Lai China 10 84 0.3× 98 0.8× 36 0.5× 137 2.7× 6 0.1× 23 292
B. Diletto Italy 9 98 0.3× 35 0.3× 11 0.2× 34 0.7× 92 2.0× 22 208
Laura Valori Italy 6 148 0.5× 58 0.5× 13 0.2× 48 1.0× 21 0.5× 7 221

Countries citing papers authored by K. Slimane

Since Specialization
Citations

This map shows the geographic impact of K. Slimane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Slimane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Slimane more than expected).

Fields of papers citing papers by K. Slimane

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Slimane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Slimane. The network helps show where K. Slimane may publish in the future.

Co-authorship network of co-authors of K. Slimane

This figure shows the co-authorship network connecting the top 25 collaborators of K. Slimane. A scholar is included among the top collaborators of K. Slimane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Slimane. K. Slimane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Shao, Zhi‐Ming, Li Cai, J. Feng, et al.. (2021). 238P BOLERO-5: A phase II study of everolimus and exemestane combination in Chinese post-menopausal women with ER+/HER2- advanced breast cancer. Annals of Oncology. 32. S463–S463. 6 indexed citations
2.
3.
Lamuraglia, Michele, Stéphane Oudard, Bernard Escudier, et al.. (2015). mTOR-inhibitor treatment of metastatic renal cell carcinoma: contribution of Choi and modified Choi criteria assessed in 2D or 3D to evaluate tumor response. European Radiology. 26(1). 278–285. 13 indexed citations
4.
Santos, Célia Dos, Annemilaï Tijeras‐Raballand, Maria Serova, et al.. (2014). Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma. British Journal of Cancer. 112(1). 86–94. 13 indexed citations
5.
Marangoni, Elisabetta, Franck Assayag, Sophie Château‐Joubert, et al.. (2012). 333 Preclinical Testing of Everolimus in Combination with Standard Endocrine Treatments in Hormone-resistant Patient-derived Luminal Breast Cancer Xenografts. European Journal of Cancer. 48. 102–102. 1 indexed citations
6.
7.
Escudier, Bernard, Sergio Bracarda, Pablo Maroto, et al.. (2012). Open-Label Phase II Trial of First-Line Everolimus Monotherapy in Patients with Advanced Papillary Renal Cell Carcinoma: Raptor Interim Analysis. Annals of Oncology. 23. ix264–ix264. 4 indexed citations
8.
Cottu, P., Franck Assayag, Ivan Bièche, et al.. (2012). Abstract P6-04-14: Targeting the PI3K/mTOR pathway in patient-derived xenograft models of endocrine resistant luminal breast cancer. Cancer Research. 72(24_Supplement). P6–4. 2 indexed citations
9.
Porcher, Raphaël, Delphine Kérob, N. Dupin, et al.. (2011). Multicentric phase II clinical trial evaluating the role of everolimus (RAD001) in endemic or classic Kaposi’s sarcoma (C06-46).. Journal of Clinical Oncology. 29(15_suppl). 10067–10067. 2 indexed citations
10.
Lucidarme, Olivier, Michele Lamuraglia, Bernard Escudier, et al.. (2011). Interest of CHOI and modified CHOI criterion for evaluation of metastatic renal cell carcinomas (mRCC) patients treated with Everolimus. Cancer Imaging. 11(1A). S41–S42. 1 indexed citations
11.
Caglio, Silvia, K. Slimane, Cédric Le May, & Bernard Escudier. (2010). Open-label phase II trial of everolimus monotherapy in treatment-naive patients with advanced papillary renal cell carcinoma.. Journal of Clinical Oncology. 28(15_suppl). TPS234–TPS234. 6 indexed citations
12.
13.
Caglio, Silvia, Anna Sundlöv, K. Slimane, Carl May, & Bernard Escudier. (2009). 7156 Open-label phase II trial of everolimus monotherapy for patients with advanced papillary renal cell cancer (RAPTOR): rationale and design. European Journal of Cancer Supplements. 7(2). 440–440. 1 indexed citations
14.
Slimane, K., Fabrice André, Suzette Delaloge, et al.. (2004). Risk factors for brain relapse in patients with metastatic breast cancer. Annals of Oncology. 15(11). 1640–1644. 131 indexed citations
15.
Fizazi, Karim, K. Slimane, F. Eschwège, P. Wibault, & R. de Crevoisier. (2004). Early undetectable serum PSA is an independent predictive factor of progression-free survival (PFS) and bone metastases in patients with localized prostate cancer treated by androgen deprivation and radiotherapy. Journal of Clinical Oncology. 22(14_suppl). 4684–4684. 1 indexed citations
16.
Rouzier, Roman, K. Slimane, Jean-Rémi Garbay, et al.. (2004). Prognostic role of serum Ca 15–3 and circumstances of diagnostic in advanced breast cancer: Data from a prospective randomized trial. Journal of Clinical Oncology. 22(14_suppl). 810–810. 1 indexed citations
17.
Alimi, Yves, et al.. (1998). Rupture of an abdominal aortic aneurysm after endovascular graft placement and aneurysm size reduction. Journal of Vascular Surgery. 28(1). 178–183. 142 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicola Fenwick Breakdown of academic impact, for papers by Drew Baldwin Breakdown of academic impact, for papers by Antonella Fontana Breakdown of academic impact, for papers by Shireen Parsai Breakdown of academic impact, for papers by Hirotoshi Kubokura Breakdown of academic impact, for papers by Ivica Ratoša Breakdown of academic impact, for papers by Anna Skakodub Breakdown of academic impact, for papers by Renchun Lai Breakdown of academic impact, for papers by B. Diletto Breakdown of academic impact, for papers by Laura Valori
Rankless by CCL
2026